CD19-specific chimeric antigen receptor (CAR) T-cell therapy has achieved remarkable efficacy in patients with relapsed or refractory B-cell acute lymphoblastic leukaemia (B-ALL) [
- Maude S.L.
- Frey N.
- Shaw P.A.
- et al.
Chimeric antigen receptor T cells for sustained remissions in leukemia.
N Engl J Med. 2014; 371: 1507-1517
], and two anti-CD19 CAR-T cell products were approved by U.S. Food and Drug Administration for clinical use in 2017. However, a suitable target antigen for acute myeloid leukaemia (AML) or T-cell acute lymphoblastic leukaemia (T-ALL) has not been identified yet, although some preclinical studies and clinical trials have shown promising effects of CAR-T cell therapy against AML or T-ALL by targeting different antigens such as CD123, CD44v6, Lewis Y, FLT3 or CD7 [
- Pan J.
- Yang J.F.
- Deng B.P.
- et al.
High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients.
Leukemia. 2017; 31: 2587-2593
- Hofmann S.
- Schubert M.L.
- Wang L.
- et al.
Chimeric antigen receptor (CAR) T cell therapy in acute myeloid leukemia (AML).
J Clin Med. 2019; 8: 200
- Gomes-Silva D.
- Srinivasan M.
- Sharma S.
- et al.
CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies.
Blood. 2017; 130: 285-296
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to European Journal of Cancer
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Chimeric antigen receptor T cells for sustained remissions in leukemia.N Engl J Med. 2014; 371: 1507-1517
- High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients.Leukemia. 2017; 31: 2587-2593
- Chimeric antigen receptor (CAR) T cell therapy in acute myeloid leukemia (AML).J Clin Med. 2019; 8: 200
- CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies.Blood. 2017; 130: 285-296
- Anti-CD19 chimeric antigen receptor targeting of CD19 + acute myeloid leukemia.Leuk Res Rep. 2018; 9: 42-44
- Phenotypical characteristics of acute myelocytic leukemia associated with the t(8;21) (q22;q22) chromosomal abnormality: frequent expression of immature B-cell antigen CD19 together with stem cell antigen CD34.Blood. 1992; 80: 470-477
- Remission of acute myeloid leukemia with t(8;21) following CD19 CAR T-cells.Leukemia. 2020; 34: 1939-1942
- Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel.J Hematol Oncol. 2018; 11: 35
- Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia.Blood Cancer J. 2020; 10: 15
- Understanding the mechanisms of resistance to CAR T-cell therapy in malignancies.Front Oncol. 2019; 9: 1237
- A bump in the road: how the hostile AML microenvironment affects CAR T cell therapy.Front Oncol. 2020; 10: 262
Published online: June 11, 2021
Accepted: April 30, 2021
Received in revised form: April 21, 2021
Received: February 22, 2021
© 2021 Elsevier Ltd. All rights reserved.